REGENXBIO  logo
REGENXBIO RGNX
$ 7.16 -1.1%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

REGENXBIO Operating Income | RGNX

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula
Operating profit = Revenue – Operating expenses
Features of the metric
  • Evaluates business efficiency
    Shows how well the company controls its production and administrative costs.
  • Independent of financial structure
    Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
  • Main source for growth
    High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income REGENXBIO

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-161 M -233 M -268 M -263 M 160 M -119 M -149 M 88.1 M -75.9 M -65.3 M -23.1 M -3.68 M -4.78 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
160 M -268 M -86 M

Quarterly Operating Income REGENXBIO

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-35.5 M 29.3 M -83.4 M -57.6 M -52.4 M -63.3 M 12.1 M -51.4 M -62.1 M -56 M -63.9 M -63.9 M -65 M -73.1 M -66.2 M -57.8 M -71 M -62.5 M -71.5 M 314 M -57.3 M -52.2 M -44 M -53.7 M 14 M -41.8 M -37.7 M -40.3 M -35.9 M -36.9 M -35.9 M 2.45 M -22.7 M 6.35 M 102 M -16.6 M -21.3 M -15.1 M -22.9 M - -18.7 M -15 M -11.3 M - -7.35 M -6.3 M -3.99 M - -1.7 M - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
314 M -83.4 M -25.6 M

Operating Income of other stocks in the Biotechnology industry

Issuer Operating Income Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
-6.36 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-104 M - - $ 8.42 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
-142 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-28.9 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
-272 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
-136 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
-216 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-11.1 M - 4.01 % $ 150 M canadaCanada
Galapagos NV Galapagos NV
GLPG
295 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-418 K - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.08 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
-30.2 M $ 4.63 21.05 % $ 20 M israelIsrael
Leap Therapeutics Leap Therapeutics
LPTX
-41.1 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
-36.6 M - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
-62.3 M - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
-77 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
-61.1 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-1.05 B - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
-187 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-22.4 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
-27.8 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
-155 M - - $ 69.7 B britainBritain
Guardion Health Sciences Guardion Health Sciences
GHSI
-4.34 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
5.16 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
-86.8 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
-221 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
-14.7 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
-176 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
-18.7 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
-12.1 M - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-14.1 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-46.3 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-37 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.1 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-270 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
-22.7 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-34 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-64.6 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
-43.7 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
-50 M - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
-151 M - - $ 127 M usaUSA
Aravive Aravive
ARAV
-70.8 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-61.5 M - - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
-517 M $ 84.95 0.13 % $ 7.99 B usaUSA